ATYPICAL RESPONDERS LANDSCAPE REVIEW ∙ OCTOBER, 2017 44 28. Ruddy, K.J., et al., Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat, 2013. 141(3): p. 421-7. 29. Dickschen, K., et al., Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling. Springerplus, 2014. 3: p. 285. 30. van der Weide, J. and J.W. Hinrichs, The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev, 2006. 27(1): p. 17-25. 31. Thomas-Schoemann, A., et al., Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol, 2014. 89(1): p. 179-96. 32. Mokrim, M., et al., Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. BMJ Case Rep, 2014. 2014. 33. Schneider, B.P., et al., Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res, 2015. 21(22): p. 5082-91. 34. Schneider, B.P., et al., Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer, 2014. 111(6): p. 1241-8. 35. Devaud, C., et al., Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology, 2013. 2(8): p. e25961. 36. Reznikov, A., Hormonal impact on tumor growth and progression. Exp Oncol, 2015. 37(3): p. 162-72. 37. Giussani, M., et al., Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. Semin Cancer Biol, 2015. 38. Park, J.H., et al., Presence of insulin-like growth factor binding proteins correlates with tumor-promoting effects of matrix metalloproteinase 9 in breast cancer. Neoplasia, 2015. 17(5): p. 421-33. 39. Rothschild, E. and D. Banerjee, Subverting Subversion: A Review on the Breast Cancer Microenvironment and Therapeutic Opportunities. Breast Cancer (Auckl), 2015. 9(Suppl 2): p. 7-15. 40. Klemm, F. and J.A. Joyce, Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol, 2015. 25(4): p. 198-213. 41. Shinn, E.H., et al., Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev, 2013. 22(11): p. 2102-9.